
Overview and
History of ARIMIMED 1 (Anastrozole)
ARIMIMED 1 (Anastrozole) belongs to a class of drugs called aromatase inhibitors
(AIs). Aromatase inhibitors belong to
an even broader class of drugs known as anti-estrogens. The other subcategory
of drug under the anti-estrogens category is known as selective estrogen
receptor modulators, called SERMs for short. SERMs are a
class of drugs that act on
the estrogen receptor (ER). Aromatase inhibitors and SERMs are very different in their action and how
they deal with the issues of estrogen control. There is common misunderstanding
exists that SERMs, such as NOLVAMED 20 (Tamoxifen
citrate) and CLOMIMED 50 (Clomiphene
citrate), serve to lower estrogen levels. This is still a
popular rumor among the anabolic steroid using community.
SERMs serve to block the action of Estrogen at the receptor
sites in breast tissue by occupying the receptor sites in place of Estrogen so
that Estrogen itself cannot exert its effects there through receptor site
binding. SERMs will also act as Estrogens at receptor sites at other cells in
other areas of the body. SERMs do not lower circulating levels of Estrogen in
blood plasma. Aromatase inhibitors serve to do this by eliminating the
production of Estrogen through binding to and disabling the aromatase enzyme
which is responsible for the conversion (or aromatization) of androgens into
Estrogen.
ARIMIMED 1 (Anastrozole) was originally developed for the treatment of female patients suffering from advanced breast
cancer. ARIMIMED 1 (Anastrozole)is one of the newest aromatase inhibitors,
also known as a third-generation aromatase inhibitor.
Although in different ways, both aromatase inhibitors and
SERMs act to block Estrogen’s effects that happens so because it has been found
that the vast majority of breast cancers are stimulated and accelerated by
Estrogen.
ARIMIMED 1 (Anastrozole) is used among breast cancer
treatments, which is known as an adjunct treatment. Usually, that is an
additional treatment in the case when other standard treatments have failed to
meet proper expectations.
Estrogen plays a key role in the proper maintenance of bone
and its mineral retention, and this will become significantly reduced following
the vast reduction of Estrogen levels resultant of ARIMIMED 1 (Anastrozole) administration.
ARIMIMED 1 (Anastrozole) was the very first aromatase inhibitor for many
bodybuilders. Nowadays it is the most popular aromatase inhibitor used among
anabolic steroid users for Estrogen control. The use among the anabolic steroid
using athletes is for the control of almost all Estrogen-related side effects:
the manifestation of gynecomastia, water retention and bloating, rising blood
pressure (as a result of water retention increases from Estrogen).
Research
has shown that ARIMIMED 1 (Anastrozole) use in males has been effective
enough to reduce circulating blood plasma levels of Estrogen by 50% at only a
dose
of 0.5 – 1mg daily. This is a very
considerable decrease in men, but those numbers differ from the 80% reduction
in female breast cancer patients. We shouldn't forget the fact of how Estrogen
relates to the female physiology and that it is different from males.
Some male patients suffer from abnormally high
Estrogen levels of many different reasons and ARIMIMED 1 (Anastrozole) has been used in the medical
field to fight that issue. ARIMIMED 1 (Anastrozole) has been used to treat male adolescents that
exhibit excessive Estrogen levels during puberty, resulting in unwanted
pubertal gynecomastia.
Chemical
Characteristics of ARIMIMED 1 (Anastrozole)
ARIMIMED 1 (Anastrozole) is a non-steroidal aromatase inhibitor. That is
important to note that it does not possess the characteristic four ring
cycloalkane ring carbon structure common of all types of steroids.
Properties of
ARIMIMED 1 (Anastrozole)
ARIMIMED 1 (Anastrozole) effects on serum Estrogen level control can be
quite dramatic even at a dose of 1mg daily. The amount of Estrogen suppression
resulting from this dose has been demonstrated to be over 80% in patients.
ARIMIMED 1 (Anastrozole) can be very effective at
inhibiting the aromatase enzyme and thereby reducing Estrogen levels. ARIMIMED 1 (Anastrozole) is typically administered only
to post-menopausal females, and/or utilized when other first-line treatments
for breast cancer has failed.
ARIMIMED 1 (Anastrozole) and another aromatase
inhibitor Letrozole, are
both classified as non-steroidal and non-suicidal aromatase inhibitors that
compete with the substrate for binding to the enzyme active site. Because being
non-suicidal aromatase inhibitors, both compounds compete with the enzyme’s
traditional ‘targets’ rather than being assured a permanent spot. Bodybuilders
and athletes utilizing anabolic steroids will usually choose aromatase
inhibitors such as ARIMIMED 1 (Anastrozole) because that can eliminate rising Estrogen
levels at its root cause: aromatase. By disabling the aromatase enzyme,
supraphysiological levels of aromatizable androgens (such as TESTOMED E 250
(Testosterone Enanthate), DIANAMED 10
(Methandienone), EQUIMED 250 (Boldenone
undecylenate), etc.) cannot convert into Estrogen, thereby eliminating any possible
risk of Estrogen-related side effects.
ARIMIMED 1
(Anastrozole) Side Effects
Mainly ARIMIMED 1 (Anastrozole) is an ancillary compound for
Estrogen control within the body. Because of that ARIMIMED 1 (Anastrozole) is generally well tolerated by
male users.
Like with any other
steroid, some side effects are possible. This primarily exists in the form of
excess reduction of blood plasma levels of Estrogen in the body, as well as
long-term Estrogen suppression. ARIMIMED 1 (Anastrozole) affect females users much more
than male users. Regarding Estrogen reduction and suppression, it must be
outlined that unlike SERMs (Selective Estrogen Receptor Modulators) such as NOLVAMED 20 (Tamoxifen
citrate) or CLOMIMED 50 (Clomiphene
citrate), ARIMIMED 1 (Anastrozole) belongs to the family of
aromatase inhibitors. Meaning that it serves to disable the aromatase enzyme,
which is responsible for the aromatization or conversion of Testosterone into
Estrogen. ARIMIMED 1 (Anastrozole) reduces total circulating
Estrogen levels at the root source as opposed to SERMs, which serve to merely
block the activity of Estrogen at select receptor sites.
There is some evidence that the use of ARIMIMED 1 (Anastrozole) results in the increased incidence and
probability of experiencing bone fractures. Although this is more applicable to
a female-specific side effect of ARIMIMED 1 (Anastrozole) use, Estrogen does play an
important role in the promotion and retention of bone mineral content in males
as well. Some studies discovered that ARIMIMED 1 (Anastrozole) does negatively impact calcium turnover
levels in bone tissue with even short term use. Lethargy and fatigue are common
symptoms associated with ARIMIMED 1 (Anastrozole) use.
As it happens with nearly all Estrogen
reduction compounds, a reduction in circulating Estrogen levels means that the
important role that Estrogen plays in the CNS (Central Nervous System) is
reduced, thus resulting in possible instances of chronic fatigue. Usually, this
is the result of Estrogen levels being reduced to levels that are considered
far too low to be healthy.
ARIMIMED 1 (Anastrozole) has one significant side effect
– that is its negative impact on blood cholesterol profiles. ARIMIMED 1 (Anastrozole) will also decrease HDL (good)
cholesterol and increase LDL (bad cholesterol). This happens because Estrogen
is responsible for the promotion of healthy cholesterol levels in the body, and
a disruption of normal blood plasma levels of Estrogen will indeed throw that
off. That is important to realize that the more severe the reduction of
Estrogen, the more severe the cardiovascular impacts will be in this area.
One very importantARIMIMED 1 (Anastrozole) side effect is the possibility of Estrogen rebound.
This side effect exists in particular with two of the three most popular
aromatase inhibitors (ARIMIMED 1 (Anastrozole) and Letrozole). The third aromatase inhibitor, AROMAMED 25 (Exemestane) is different and does not have the possibility of Estrogen
rebound. This is so because unlike AROMAMED 25 (Exemestane), ARIMIMED 1 (Anastrozole) is a non-suicidal aromatase inhibitor. ARIMIMED 1 (Anastrozole) will bind with and disable the aromatase enzyme, but it does
not do it permanently. At some point, ARIMIMED 1 (Anastrozole) will dissociate with the enzyme and the enzyme will then be
free to do its job again in the body.
For the users that means the risk of a
rebound of Estrogen levels (and thus, Estrogen related side effects) if ARIMIMED 1 (Anastrozole) use is stopped too soon or abruptly after beginning
use.
ARIMIMED 1
(Anastrozole) Cycles and Use
ARIMIMED 1 (Anastrozole) is used as a medication in the treatment of post-menopausal
female breast cancer where Estrogen has been determined to be the prime cause.
In such cases, the prescription dosing and administration of ARIMIMED 1 (Anastrozole) are 1mg taken once per day, until the progression of cancer
has stopped.
ARIMIMED 1 (Anastrozole)
For Gynecomastia and Estrogen Control On-Cycle
For this purpose, ARIMIMED 1 (Anastrozole) should be used at a general range of 0.5 – 1mg per day and
can be adjusted depending on the user's tolerance and reaction to the compound.
Users should manage their ARIMIMED 1 (Anastrozole) dosage according to their response. For some
people, even 0.5mg/day can be too much (or too little). It should always be
remembered that the purpose of the ARIMIMED 1 (Anastrozole) use is Estrogen control during a cycle, not total
elimination of Estrogen levels.
ARIMIMED 1 (Anastrozole)
For Post Cycle Therapy (PCT)
ARIMIMED 1 (Anastrozole) has been shown in studies to assist in the
generation of endogenous natural Testosterone production in males. Therefore ARIMIMED 1 (Anastrozole) dosage of 0.5mg to 1mg per day should be sufficient for the
duration of any PCT length. ARIMIMED 1 (Anastrozole) possesses a half-life of approximately 48 hours. It is
important to realize that peak blood plasma levels will not be achieved with ARIMIMED 1 (Anastrozole) until a full week (7 days) of consistent use is
achieved. ARIMIMED 1 (Anastrozole) can be taken at any time of day, with or without food.
Chemical info /
Information
Anastrozole (AKA Arimidex)
Chemical Name: 2,2′-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
Molecular Weight: 293.366 g/mol
Formula: C17H19N5
Original Manufacturer: AstraZeneca
Elimination half-life: 46 – 48 hours (approximately 2 days)
Detection Time: 2 weeks
Anabolic Rating: N/A
Androgenic Rating: N/A
Leave a Comment